Kymera Therapeutics Inc
(NAS:KYMR)
$
50.05
-1.84 (-3.55%)
Market Cap: 3.24 Bil
Enterprise Value: 2.90 Bil
PE Ratio: 0
PB Ratio: 3.63
GF Score: 47/100 Kymera Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021 / 05:15PM GMT
Release Date Price:
$64.17
(+2.26%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Great. Welcome, everyone. Thanks for joining. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research. Very happy to have with me Nello Mainolfi, CEO of Kymera Therapeutics. Nello, welcome.
Nello Mainolfi
Kymera Therapeutics, Inc. - Co-Founder, President, CEO & Director
Thanks, Vikram. Good to be here.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Yes, great to have you. So before we get started, I need to read a brief disclosure. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
One more housekeeping item before we go ahead and get started in the discussion here with Nello. If any of you have questions as the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot